Respiratory

#ENA Respiratory #Immunology / Virology & Vaccines #Phase II trial #Respiratory

Community study tests respiratory protective nasal spray

ENA Respiratory has dosed the first participants in Part B of its Phase IIa community study of INNA-051, a virus-agnostic, dry powder nasal spray.  INNA-051 is designed to prime the natural antiviral host defences in the nose where common respiratory viruses like rhinovirus, flu, RSV and coronaviruses… Read More

#News

#Infex Therapeutics #Monoclonal antibodies #Phase II trial #Respiratory

New Phase IIa data for RESP-X revealed at ERS Congress 2026

Infex Therapeutics has presented new data from its Phase IIa study of RESP-X (INFEX702), a first-in-class anti-virulence monoclonal antibody, in non-cystic fibrosis bronchiectasis (NCFB) patients colonised with Pseudomonas aeruginosa (Pa).  The results were presented at the European Respiratory Society (ERS) Congress 2026 in Barcelona, Spain. … Read More

#News

Influenza
#Covid-19 #Flu #Immunology / Virology & Vaccines #Respiratory #University of Buffalo

Nanoparticle vaccine shows potential against ‘tripledemic’

A single-shot vaccine under development at the University at Buffalo in the US could protect against flu, Covid-19 and respiratory syncytial virus (RSV) simultaneously.   In a study published in Science Advances, the researchers found that their three-in-one vaccine triggered protective immunity against all three respiratory… Read More

#Editor's Choice #News

Lungs
#Kither Biotech #Peptides #Phase I trial #Respiratory

Kither completes Phase I trial of inhaled peptide therapy

Kither Biotech has announced the successful completion of its Phase I clinical study of KIT2014 for respiratory diseases in healthy participants.  “We are pleased to report the successful completion of this first-in-human Phase I study with KIT2014, a significant milestone for Kither Biotech,” said Dr Dimitrios Goundis,… Read More

#News

#Antibody drug conjugate (ADC) #Cytokine Release Syndrome (CRS) #Diabetes #Eli Lilly #GLP-1 #Idiopathic pulmonary fibrosis #Lung disease #Mergers and acquisitions #MHRA #Obesity #Poolbeg Pharma #Respiratory #Weight loss

DDW Highlights: 28 April 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, an obesity drug proved it could improve liver health independent of weight… Read More

#Podcasts

#Antibody drug conjugate (ADC) #Cytokine Release Syndrome (CRS) #Diabetes #Eli Lilly #GLP-1 #Idiopathic pulmonary fibrosis #Lung disease #Mergers and acquisitions #MHRA #Obesity #Poolbeg Pharma #Respiratory #Weight loss

This week in Drug Discovery (20 – 24 April) 

News round-up for 20 – 24 April by Bruno Quinney, Content Team at DDW.  This week, an obesity drug could improve liver health independent of weight loss. Elsewhere, Lilly is back in the news for both its type 2 diabetes drug and the company’s latest acquisition.  The top stories:   … Read More

#News

#Idiopathic pulmonary fibrosis #Lung disease #Respiratory

Digital lung ‘twins’ could predict drug efficacy in humans 

Digital lung ‘twins’ could help predict the efficacy of inhaled drugs in patients with respiratory problems.  Healthcare company Ebenbuild has developed lung digital twin technology, which uses patient-specific models to predict drug deposition.  According to a study published in Nature Communications Medicine, the validated technology… Read More

#News

GSK offices
#CHMP #European Medicines Agency #GSK #Respiratory

CHMP supports two GSK respiratory drugs for 2026 approval

GSK has announced positive opinions from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommending the approval of two new potential medicines for respiratory diseases.  Depemokimab has been recommended as add-on maintenance treatment for severe asthma with type 2 inflammation (12+) and… Read More

#News #Regulatory

Close up of vaccine syringe
#Immunology / Virology & Vaccines #Mergers and acquisitions #Respiratory #Sanofi #Vaccines #Vicebio

Harnessing molecular clamp technology for respiratory vaccines

Sanofi explores the acquisition of Vicebio and its Molecular Clamp technology, highlighting how it strengthens the company’s respiratory vaccine portfolio with next-generation combination candidates. Q: Sanofi has described the acquisition of Vicebio as a step toward next-generation combination vaccines. What gaps or opportunities does this address in your… Read More

#Exclusive Content

#Celea Therapeutics #Idiopathic pulmonary fibrosis #Lung disease #PureTech #Respiratory

Celea Therapeutics launches into respiratory disease space

PureTech Health has announced the launch of a new founded entity Celea Therapeutics to deliver therapies for serious respiratory diseases.   Its lead programme, deupirfenidone (LYT-100), is a Phase III-ready therapeutic candidate that holds promise across multiple fibrotic and inflammatory lung conditions and is initially being advanced for… Read More

#Business & Investment #News

Respiratory syncytial virus
#ENA Respiratory #Immunology / Virology & Vaccines #Phase II trial #Respiratory #University of Maryland

Vaccine centre hosts study of antiviral host defence enhancer

ENA Respiratory and the University of Maryland have announced plans to partner on a Phase II study of INNA-051 for the prevention of illness due to viral respiratory infections.  Dr Justin Ortiz, Professor of Medicine at the University of Maryland School of Medicine’s Center for Vaccine and… Read More

#News

Influenza virus
#Collaboration #Ethris #Lonza #mRNA #mRNA-based vaccines #Respiratory

Partners develop non-invasive mRNA vaccines

Ethris and Lonza have announced a collaboration to develop room-temperature stable, spray-dried formulations of mRNA-based vaccine candidates.  The vaccines are designed for mucosal delivery and offer a promising approach to combat respiratory diseases.  Room-temperature stability aims to address significant supply chain challenges associated with some… Read More

#News

Vaccine
#Clinical trials #Drug development #Funding #Immunology / Virology & Vaccines #Respiratory #Vicebio

New financing and clinical trial for RSV/hMOV bivalent vaccine

Vicebio has announced a $100 million Series B financing, which will be used to develop next-generation vaccines for respiratory viruses.   The development will utilise Vicebio’s Molecular Clamp technology, discovered at The University of Queensland. The technology stabilises viral glycoproteins in their highly immunogenic ‘prefusion’ conformation, crucial for… Read More

#News

#Cystic fibrosis #Ireland #Paediatrics #Respiratory #Vertex

Landmark study supports use of cystic fibrosis drug in newborns

A cystic fibrosis drug targeting the basic defect that causes the condition has been shown to be safe and effective in newborns aged four weeks and above, new research has found. The study, involving RCSI University of Medicine and Health Sciences and Children’s Health Ireland, included… Read More

#News

Lungs
#Angiotensin II type 2 receptor agonists (ATRAGs) #Respiratory #Vicore Pharma

Podcast: Exploring the potential of a new class of drug candidates

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Ahmed Mousa, CEO… Read More

#News

GSK offices
#Asthma #GSK #Mergers and acquisitions #Monoclonal antibodies #Respiratory

GSK expands respiratory pipeline with Aiolos Bio acquisition

GSK is to acquire Aiolos Bio for a $1 billion upfront payment and up to $400 million in regulatory milestone payments. The acquisition includes Aiolos’ AIO-001, a potentially best-in-class, long-acting anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody ready to enter Phase II clinical development for asthma, with… Read More

#Business & Investment #News